GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » NonCurrent Deferred Liabilities

Clarity Pharmaceuticals (Clarity Pharmaceuticals) NonCurrent Deferred Liabilities : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Clarity Pharmaceuticals's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $0.00 Mil.

Clarity Pharmaceuticals NonCurrent Deferred Liabilities Historical Data

The historical data trend for Clarity Pharmaceuticals's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals NonCurrent Deferred Liabilities Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
NonCurrent Deferred Liabilities
- -

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial - - - - -

Clarity Pharmaceuticals NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.